Gamma linoleic acid (GLA, Epogam) is considered a safe and effective modality in the treatment of atopic dermatitis (AD) in which impaired function of the enzyme, delta-6-desaturase, has been reported to result in reduced levels of GLA, desaturated fatty acids.

We performed this study to observe the changes of skin surface conditions measured objectively by bioengineering methods in relation to clinical improvement after treatment with GLA (Epogam®) in children with AD.

Thirty-four children with AD were treated with GLA (Epogam®) and evaluated with clinical parameters.The changes of skin surface conditions were monitored by non-invasive experimental instruments.

There was a significant decrease of transepidermal water loss (TEWL) and gradual improvements in clinical severity after 12 weeks of GLA (Epogam®) treatment. The change of skin surface pH was statistically significant on the antecubital fossa and abdomen except the popliteal fossa. The other parameters including skin surface hydration and skin surface lipid did not show consistent changes.

Clinical improvement of AD with GLA (Epogam) seemed to be achieved by the reduction of TEWL.